Therapeutic strategies in Parkinson's disease

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 2, Issue 2, 2008, Pages 135-147

  Bharath, Muchukunte M S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Antioxidant; Catechol O methyl tranferase; Clinical trials; Coenzyme Q10; Dopamine agonists; Dyskinesia; L dopa; Monoamine oxidase; Neurodegeneration; Neuroprotecive; Oxidative stress; Parkinson's disease; Patents; Pharmacotherapy; Protein aggregation

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; AMANTADINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATINE; CURCUMIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ISPAGULA; ISTRADEFYLLINE; LEVODOPA; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PERGOLIDE; PLACEBO; POLYPHENOL; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; UBIDECARENONE; UNINDEXED DRUG;

ADJUVANT THERAPY; BLURRED VISION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIAPHORESIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSKINESIA; EVIDENCE BASED MEDICINE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERTENSION; LIVER TOXICITY; MENTAL HEALTH; MONOTHERAPY; MOTOR DYSFUNCTION; MUCOSAL DRYNESS; NAUSEA; NEUROPROTECTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ON OFF PHENOMENON; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREMOR; URINE RETENTION;

EID: 55849120855     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221408784534268     Document Type: Review

References (194)

1. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 2006; 5:235-245.
3. Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol 2002; 12: 499-510.
4. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007; 16, 2: R183-194.
5. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992; 31: 119-130.
6. Koliatsos VE, Ratan RR(ed.). Parkinson's disease. In Burke RE, Cell death and disease of the nervous system. Totowa, NJ Humana Press. 1998; 459-475.
7. Adams JD Jr., Chang ML, Klaidman L. Parkinson's disease-redox mechanisms. Curr Med Chem 2001; 8: 809-814.
8. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative diseases. Curr Med Chem 2001; 8: 721-738.
9. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-827.
10. Sriram K, Shankar SK, Boyd MR, Ravindranath V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid mediated neurodegeneration. J Neurosci 1998; 18: 10287-10296.
11. Jha N, Jurma O, Lalli G, et al. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson's disease. J Biol Chem 2000; 275: 26096-27001.
12. Lin TK, Hughes G, Muratovska A, et al. Specific modification of mitochondrial protein thiols in response to oxidative stress: A proteomics approach. J Biol Chem 2002; 277: 17048-17056.
13. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006; 26: 5256-5264.
14. Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986; 67: 269-274.
15. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 1993; 146: 6-13.
16. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002; 64: 1037-1048.
17. Danielson SK, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Rad Biol Med 2008; 44: 1787-1794.
18. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004; 56:149-162.
19. Sullivan PG, Dragicevic NB, Deng JH, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 2004; 279: 20699-20707.
20. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005; 102: 3413-3418.
21. Kikuchi S, Shinpo K, Tsuji S, et al. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res 2003; 964: 228-236.
22. Sullivan PG, Dragicevic NB, Deng JH, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 2004; 279: 20699-20707.
23. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996; 55: 259-272.
24. Rajagopalan S, Andersen JK. Alpha synuclein aggregation: Is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech Ageing Dev 2001; 122: 1499-1510.
25. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron 2006; 52: 33-38.
26. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced Substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004; 186: 158-172.
27. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski, JQ, Lee VM. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007; 170: 658-666.
28. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292-1295.
29. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 2002; 418: 291.
30. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002; 41: 10209-10217.
31. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha -synuclein impairs complex I in human dopaminergic neuronal cultures and Parkinson's disease brain. J Biol Chem 2008; 283: 9089-9100.
32. Abeliovich A, Beal M.F. Parkinsonism genes: Culprits and clues. J Neurochem 2006; 99: 1062-1072.
33. Polymeropoulos MH. Genetics of Parkinson's disease. Ann N Y Acad Sci 200; 920: 28-32.
34. Spillantini MG., Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
35. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
36. Gispert S, Del Turco D, Garrett L, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003; 24: 419-429.
37. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's diseaselinked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 8968-8973.
38. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006; 26: 41-50.
39. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21: 9549-9560.
40. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313: 324-328.
41. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365: 412-415.
42. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-425.
43. Bosgraaf L, Van Haastert PJ. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 2003; 1643: 5-10.
44. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006; 139: 791-794.
45. West AB, Moore DJ, Biskup S, et al. Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102: 16842-16847.
46. Gloeckner CJ, Kinkl N, Schumacher A, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006; 15: 223-232.
47. Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006; 23: 329-341.
48. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-305.
49. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605- 608.
50. Darios F, Corti O, Lucking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria dependent cell death. Hum Mol Genet 2003; 12: 517-526.
51. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003; 100: 4078-4083.
52. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279; 18614-18622.
53. Kuroda Y, Mitsui T, Kunishige M, et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006; 15: 883-895.
54. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
55. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 2006; 356: 1036-1048.
56. Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005; 280: 43150- 43158.
57. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005; 45: 489-496.
58. Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005; 102, 5215-5220.
59. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5: 213-218.
60. Park J, Kim SY, Cha G H, Lee SB, Kim S, Chung J. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 2005; 361: 133-139.
61. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56: 336-341.
62. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005; 14: 3477-3492.
63. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-1166.
64. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157-1161.
65. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for ParkAnson's disease: an evidence-based review: Report of the quality standards subcommittee of the American academy of neurology. Neurology 2002; 58: 11-17.
66. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 2001; 113: 851-854.
67. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 2001; 56: S1-S88.
68. Almeida QJ, Hyson HC. The evolution of pharmacological treatment for Parkinson's disease. Recent patents on CNS drug Discov 2008; 3: 50-54.
69. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study. Brain 2000; 123: 2297-2305.
70. Ahlskog JE, Muenter MD. Frequency of L-dopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
71. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007; 53: 214-222.
72. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677- 687.
73. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/L-dopa in Parkinson's disease. A multi-center 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23-27.
74. Stanley F, David O, Ira S, et al. L-dopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
75. Rao SS, Hofmann LA, Shakil A. Parkinson's disease: Diagnosis and treatment. Am Fam Physician 2006; 74:2046-2054.
76. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with L-dopa. Arch Neurol 1969; 21: 343-354.
77. Schwartz AM, Olanow CW, Spencer A. A double-blind controlled study of MK-486 in Parkinson's disease. Trans Am Neurol Assoc 1973; 98: 301-303.
78. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with L-dopa combined with carbidopa versus treatment with L-dopa alone. Lancet 1973; 2: 1459-1462.
79. Lieberman AN, Derby BM, Feigenson J, et al. MK 486 and L-dopa in treatment of Parkinsonism. Dis Nerv Syst 1973; 34: 167-171.
80. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing off" phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-1071.
81. Olanow WC. Tolcapone and hepatotoxic effects. Arch Neurol 2000; 57: 263-267.
82. Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 2003; 28: 1035-1040.
83. Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant 1997; 6: 309-315.
84. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984; 43: 990-993.
85. Spina MB, Cohen G. Exposure of striatal corrected synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988; 247: 502-507.
86. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
87. Pedrosa R, Soares-da-Silva P. Oxidative and nonoxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol 2002; 137: 1305-1313.
88. Muriel MP, Bernard V, Levey AI, et al. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 1999; 46: 103-111.
89. Muriel MP, Orieux G, Hirsch EC. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord 2002; 17: 1174-1179.
90. Reynolds GP, Riederer P, Rausch WD. Dopamine metabolism in human brain: effects of monoamine oxidase inhibition in vitro by (-) deprenyl and (+) and (-) tranylcypromine. J Neural Transm 1980; 16: 173-178.
91. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-432.
92. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 1997; 68: 33-39.
93. Tatton WG, Ju WY, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis, J Neurochem 1994; 63: 1572-1575.
94. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenylrelated compounds in controlling neurodegeneration. Neurology 1996; 47: S171-183.
95. Olanow CW, Calne D. Does selegeline monotherapy in Parkinson's disease act bysymptomatic or protective mechanisms? Neurology 1992; 42 (4): 13-26.
96. Olanow CW, Mytilineou C, Tatton W. Current status of selegeline as a neuroprotective agent in Parkinson's disease. Mov Disord 1998; 13(1): 55-58.
97. Ira S, Stanley F, David Oakes, et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
98. Stern MB, Marek KL, Freidman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004; 19: 916-923.
99. Rascol O, Brooks D, Melamed E, et al. Rasagaline as an adjunct to L-dopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagaline given once daily, study): A randomised, doubleblind, parallel-group trial. Lancet 2003; 365: 947-954.
100. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006; 248: 78-83.
101. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506.
102. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of Rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007; 29: 1825-1849.
103. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104.
104. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces L-dopainduced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 13: 798-802.
105. Verhagen ML, Del Dotto P, Blanchet PJ, et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998; 14: 75-82.
106. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004; 111: 1375-1446.
107. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18: 389-396.
108. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997; 49: S34-S48.
109. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994; 738: 222-229.
110. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207-213.
111. Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopainduced toxicity by stimulating D(2)receptors. Exp Neurol 1999; 159: 98-104.
112. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62: 1034-1038.
113. Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992; 10: 527-540.
114. Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol 1987; 45: 551-554.
115. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: Insight into clinical and research studies relevant to Parkinson's disease. Pharmacological reports 2005; 57:701-712.
116. Blin O. The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol 2003; 16: Suppl 1, S9-S12.
117. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged- Fischer-344 rats. Neurobiol Aging 1992; 13: 339-351.
118. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn Ther 1995; 329: 221-230.
119. Gille G, Rausch WD, Hung ST, et al. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 2002; 109: 633-643.
120. Uberti D, Piccioni L, Colzi A, Bravi D, Canonico PL, Memo M. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol 2002; 434: 17-20.
121. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-1183.
122. Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2, and D-3 receptors, Eur J Pharmacol 1999; 366: 293-300.
123. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-151.
124. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005; 11: 253-272.
125. Rascol O, Brooks DJ, Korczyn AD, et al. For the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or Ldopa. N Engl J Med 2000; 342: 1484-1491.
126. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
127. Lieberman A. Dopamine agonists used as monotherapy in de novo Parkinson's disease patients: Comparisons with selegeline. Neurology 1992; 42 (4): 37-40.
128. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double blind, placebo controlled, parallel-group study. Neurology 1997; 49: 162-168.
129. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel opamine agonist, as monotherapy in mild to moderate Parkinson's disease: the Pramipexole Study Group. Neurology 1997; 49: 724 -728.
130. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial. Mov Disord 2005; 20: 602-610.
131. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004; 17: 393-398.
132. Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: Implications for dyskinesia. Exp Neurol 2004; 185: 36-46.
133. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-682.
134. Nomoto M, Nagai M, Nakatsuka A, et al. Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease. J Neurol 2006; 253(3): 53- 59.
135. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of L-dopa in parkinsonian patients. Neurology 1994; 44: 913-919.
136. Parkinson Study Group. Entacapone improves motor fluctuations in L-dopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-755.
137. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to L-dopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309 -1314.
138. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of L-dopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drugnaive primates. Mov Disord 2005; 20: 306-314.
139. Olanow CW. Tolcapone and hepatotoxic effects: Tasmar Advisory Panel. Arch Neurol 2000; 57: 263-267.
140. Boireau A, Dubédat P, Bordier F, et al. Riluzole and experimental parkinsonism: Antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994; 5: 2657-2660.
141. Boireau A, Miquet JM, Dubédat P, Meunier M, Doble A. Riluzole and experimental parkinsonism: Partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 1994; 5: 2157-2160.
142. Hauser RA, Hubble JP, Truong DD. Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297-303.
143. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-671.
144. Vergez, J.A., Lanier, A.B., Feleder, E.C., Meyer, G.A., Ricci,M.A., Faour, J.: US20060063810 (2006).
145. McCreary, A.C., Van Scharrenburg, G.J.M., Tulp, M.T.M.: WO07144421 (2007).
146. McCreary, A.C., Van Scharrenburg, G.J.M., Tulp, M.T.M.: WO07144422 (2007).
147. Nyholm, D., Asberg, S., Bolsoey, R., Tutschke-Saettler, M.: WO07138086 (2007).
148. Grenier, A., Carrara, D.N.: WO08001204 (2008).
149. Mazzio, E.: US20070116779 (2007).
150. Cheng, L.: WO06012267 (2006).
151. Liu, C., Wei, Y.: WO07084839 (2007).
152. Shigenaga MK, Hagen TM and Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994; 91: 10771- 10778.
153. Ames, B.N., Hagen, T.M.: WO9857627 (1998).
154. Ames BN, Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann N Y Acad Sci 2004; 1033: 108-116.
155. Bharath S, Cochran BC, Hsu M, Liu J, Ames BN, Andersen JK. Pre-treatment with R-Lipoic acid alleviates the effects of GSH depletion in PC12 cells: Implications for Parkinson's disease therapy. NeuroToxicol 2002; 23: 479-486.
156. Ray, M., Pal, P., Singh, S., Khanna, N.M.: US20040033277 (2004).
157. Mythri RB, Jagatha B, Pradhan N, Andersen J, Bharath MM. Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? Antioxid Redox Signal 2007; 9: 399-408.
158. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008; 44: 907-917.
159. Zhu, B.T.: WO07084383 (2007).
160. Ramasamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur J Pharmacol 2006; 545: 51-64.
161. Sierra, V., M., Garcia, V.J.J., Fernandez, M.M.N., Molinero, E.C., Anguera, V. A.M.: WO07131687 (2007).
162. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15 (Suppl 1): 14-20.
163. Fernandez N, Carriedo D, Sierra M, et al. Hydrosoluble fiber ( Plantago ovata husk) and levodopa II: Experimental study of the pharmacokinetic interaction in the presence of carbidopa. Eur Neuropsychopharmacol 2005; 15: 505-509.
164. Abeliovich, A., Martinat, C.: US20060275744 (2006).
165. Nakagawa, Y., Ono, Y., Sakamoto, Y., Mizuhara, E., Nakatani, T., Takai, Y.: EP1795595 (2007).
166. Nakagawa, Y., Ono, Y., Sakamoto, Y., Mizuhara, E., Nakatani, T., Takai, Y.: US20070122882 (2007).
167. Nakagawa, Y., Ono, Y., Sakamoto, Y., Mizuhara, E., Nakatani, T., Takai, Y.: US20060239978 (2006).
168. Ono, Y., Nakagawa, Y., Sakamoto, Y.: US20060240432 (2006).
169. Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA. in vitro Differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1129-33.
170. Cho, M.S., Kim, M.-H., Moon, Y.-I., Moon, S.Y., Oh, S.K., Kim,H.S., Kim, D.-W.: WO07142449 (2007).
171. Jin K, Peel AL, Mao XO, et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 343-347.
172. Curtis MA, Penney EB, Pearson AG, et al. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci USA 2003; 100: 9023-9027.
173. Jin K, Minami M, Lan JQ, et al. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci USA 98:4710-4715.
174. Craig CG, Tropepe V, Morshead CM, Reynolds BA, Weiss S, van der Kooy D. in vivo Growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J Neurosci 1996; 16: 2649-2658.
175. Wagner JP, Black IB, DiCicco-Bloom E. Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci 1999; 19: 6006-6016.
176. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002; 99: 11946-11950.
177. Peng J, Xie L, Jin K, Greenberg DA and Andersen JK. Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinson's disease. Neuroscience 2008; in press.
178. Alitalo, K., Karkkainen, M., Haiko, P., Sainio, K., Wartiovaara, K., Thomas, J.L. Eichmann, A.: WO05030240 (2005).
179. Snow, A.D., Nguyen, B.P., Lake, T.P., Castillo, G.M., Weigele, M.: US20060199838 (2006).
180. Snow, A.D., Castillo, G.M., Choi, P.Y., Nguyen, B.P.: WO02076381 (2002).
181. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuro-protective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 2006; 23: 55-64.
182. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97:105-115.
183. Mandel S, Maor G, Youdim MB. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: Effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci 2004; 24: 401- 416.
184. Al-Abed Y.: WO08002465 (2008).
185. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
186. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
187. Cohen PS, Schmidtmayerova H, Dennis J, et al. The critical role of p38 MAP kinase in T cell HTV-I replication. MoI Med 1997; 5: 339-346.
188. Lowenberg M, Verhaar A, van den Blink B, et al. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol 2005; 175: 2293-2300.
189. Bianchi M, Bloom O, Raabe M, et al. 1996. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996; 83: 927-936.
190. Tracey KJ. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog Clin Biol Res 1998; 397: 335-343.
191. Martiney JA, Rajan AJ, Charles PC, et al. Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage deactivating agent. J Immunol 1998; 160: 5588-5595.
192. Meistrell ME 3rd, Botchkina GI, Wang H, et al. TNF is a brain-damaging cytokine in cerebral ischemia. Shock 1997; 8: 341-348.
193. Akerlund K, Erlandsson-Harris H, Tracey KJ, et al. Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-α) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol 1999; 115: 32-41.
194. Lindquist, S.L., Outeiro, T., Labaudiniere, R.: WO06034003 (2006).